{"id":"a17405e1-75ac-59cf-a933-c1e371c9dd78","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-tumor-adverse","predicate":"increases_trial_adverse_events","statement":"Grade 3–4 adverse events were reported in 28.8% with pegargiminase versus 16.9% with placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"03abc751-84e5-51df-9d3a-346e5de60ac6","mechanism_event_label":"The clinical benefit record retains the treatment tradeoff.","subject":{"id":"5c735378-f146-59bb-851a-01a54d53b84b","slug":"pegargiminase","display_name":"Pegargiminase / ADI-PEG20","entity_type_key":"protein"},"object":{"id":"90d88808-3bff-5736-8476-2b55c9bea67c","slug":"mesothelioma-treatment-adverse-events","display_name":"Grade 3–4 adverse events in the ATOMIC-Meso trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"03abc751-84e5-51df-9d3a-346e5de60ac6","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-tumor-adverse-event","event_type":"observed_relationship","label":"The clinical benefit record retains the treatment tradeoff.","description":"Grade 3–4 adverse events were reported in 28.8% with pegargiminase versus 16.9% with placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5c735378-f146-59bb-851a-01a54d53b84b","slug":"pegargiminase","display_name":"Pegargiminase / ADI-PEG20","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"90d88808-3bff-5736-8476-2b55c9bea67c","slug":"mesothelioma-treatment-adverse-events","display_name":"Grade 3–4 adverse events in the ATOMIC-Meso trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same chemotherapy-combination trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Do not attribute the combination outcome to ordinary dietary arginine intake.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Arginine collection; tissue, species, dose and formulation distinctions retained.","comparator":null,"unit":null,"notes":"","entity":{"slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The clinical benefit record retains the treatment tradeoff.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38358753/ · DOI 10.1001/jamaoncol.2023.6789","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f063669b-1848-5938-9289-5f7bd09e5a9f","evidence_kind":"source_excerpt","locator":"Lines 414-420","start_line":414,"end_line":420,"excerpt":"## arg-tumor-adverse\nThe clinical benefit record retains the treatment tradeoff.\nGrade 3–4 adverse events were reported in 28.8% with pegargiminase versus 16.9% with placebo.\nModel: Same chemotherapy-combination trial.\nLimitations: Do not attribute the combination outcome to ordinary dietary arginine intake.\nEvidence access: Primary abstract\nPegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38358753/ · DOI 10.1001/jamaoncol.2023.6789","model_system":"Same chemotherapy-combination trial.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; primary evidence access stated per claim.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"bb9a67ea-904f-5b8a-93a4-459081212bdd","stable_key":"import-fd37d270-3395-56d6-9f1c-ddda56e606f6","title":"L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"ec0e9a3fb72b7485534e4372a074ac7624a399ff962e55690eb462217b5149ec","revision_id":"af027270-5535-51ae-85ff-9c76c518c962","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}